What is NCT04512345 studying for aminolevulinic acid hydrochloride?
NCT04512345 is a clinical trial that studies aminolevulinic acid hydrochloride (ALA HCl). The study evaluates how ALA HCl is used under specific clinical “conditions” (the protocol’s eligibility criteria and intended patient population), but the exact conditions and disease setting depend on the trial’s protocol description in the registration record.
Which “conditions” (disease indications) are listed for this trial?
The trial’s listed conditions typically correspond to the clinical problem ALA HCl is being used for in that study. To answer precisely, you need the “Conditions” field from the trial registry entry (ClinicalTrials.gov). If you paste the NCT04512345 trial link or the text under the trial’s “Conditions” section, I can extract and summarize them exactly.
What factors should you check to interpret the trial’s ALA HCl “conditions” correctly?
Even when the conditions field names a disease, the protocol may still specify nuances such as:
- patient type (e.g., newly diagnosed vs. recurrent)
- clinical setting (e.g., surgery guidance vs. imaging)
- dosing and timing relative to a procedure
- inclusion/exclusion criteria that narrow what “conditions” means in practice
Those details are also in the registry record, not in the drug name alone.
Can you confirm the exact trial page content so I can extract the conditions accurately?
If you share either:
1) the ClinicalTrials.gov URL for NCT04512345, or
2) the “Conditions” lines shown on the page,
I’ll report the exact conditions studied and summarize how they relate to aminolevulinic acid hydrochloride in that protocol.
Sources
No sources were provided in the prompt, and I don’t have access to the NCT04512345 registry entry content from the information given.